Anterior Uveitis Market

Market Overview:

The 7 major anterior uveitis markets reached a value of US$ 195.7 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 316.0 Million by 2034, exhibiting a growth rate (CAGR) of 4.45% during 2024-2034.

The anterior uveitis market has been comprehensively analyzed in IMARC's new report titled "Anterior Uveitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Anterior uveitis, also known as iritis, refers to an inflammatory condition that affects the front portion of the uvea, the middle membrane of the eye. This illness typically involves inflammation of the iris, the colored part of the eye surrounding the pupil. The symptoms of the ailment may include eye redness, sensitivity to light (photophobia), blurred vision, and pain or discomfort. Patients might also experience increased tearing and a feeling of something in the eye. These signs can vary in severity and may develop suddenly. The diagnosis of anterior uveitis involves a comprehensive eye examination by an ophthalmologist. The physicians will assess the patient's medical history and indications, conduct a visual acuity test, and carefully examine the eye using a slit lamp microscope. Pupil dilation is often performed to allow a better view of the structures within the eye. Additionally, numerous diagnostic tests, such as blood workups and imaging studies, are recommended to determine the underlying cause of the inflammation.

The increasing cases of systemic diseases, such as rheumatoid arthritis and ankylosing spondylitis, are primarily driving the anterior uveitis market. In addition to this, the inflating utilization of effective medications, including corticosteroids, immunosuppressive drugs, and biologics, for managing inflammation and preventing ocular complications is also creating a positive outlook for the market. Moreover, the widespread adoption of advanced diagnostic techniques like optical coherence tomography (OCT) and anterior chamber paracentesis for accurate and timely diagnosis of the ailment is further bolstering the market growth. These technologies aid in precise visualization of the affected intraocular structures and facilitate appropriate therapeutic interventions. Apart from this, the rising application of personalized treatment approaches, tailoring the therapeutic regimen based on the specific etiology and severity of anterior uveitis, is acting as another significant growth-inducing factor. Additionally, the escalating demand for surgical interventions, such as vitrectomy and implantation of sustained-release drug delivery systems, which offer enhanced control over disease progression and better preservation of visual function, is also augmenting the market growth. Furthermore, the emerging popularity of regenerative therapies and stem cell techniques to help in restoring ocular tissue integrity and suppressing inflammation is expected to drive the anterior uveitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the anterior uveitis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for anterior uveitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the anterior uveitis market in any manner.

Recent Developments:

• In January 2024, Tarsier Pharma, Ltd. announced that it had received FDA approval under a Special Protocol Assessment (SPA) for the clinical trial protocol and organized statistical analysis of the Tarsier-04 Phase 3 trial to evaluate TRS01 eye drops for the therapy of non-infectious uveitis, including uveitic glaucoma.

Key Highlights:

• Anterior uveitis is the most common type, accounting for around 50% of uveitis cases.
• The annual incidence rate is about eight cases per 100,000 people.
• The most prevalent clinical course is acute anterior uveitis (83.81%), which is followed by chronic or persistent anterior uveitis (9.25%).
• This condition can develop at any age; however, it most typically appears in the fourth and fifth decades of life.
• Anterior uveitis more typically affects middle-aged males, and the majority of patients requiring treatment had an acute clinical course.

Drugs:

DUREZOL 0.05% (difluprednate ophthalmic emulsion) is a topical corticosteroid used to treat endogenous anterior uveitis. It works by inhibiting the inflammatory response to a variety of inciting agents that may delay or slow healing.

Dazdotuftide (TRS) is a first-in-class medication with a novel and unique mode of action for the treatment of ocular blindness in the rear and front of the eye. Dazdotuftide is a bio-inspired proprietary technology platform based on a new chemical entity (NCE) with a disruptive mechanism of action. Dazdotuftide was discovered to switch macrophages from inflammatory (M1) to IL-10-secreting anti-inflammatory (M2) macrophages.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the anterior uveitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the anterior uveitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current anterior uveitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the anterior uveitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the anterior uveitis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the anterior uveitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of anterior uveitis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of anterior uveitis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of anterior uveitis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with anterior uveitis across the seven major markets?
• What is the size of the anterior uveitis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of anterior uveitis?
• What will be the growth rate of patients across the seven major markets?
   

Anterior Uveitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for anterior uveitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the anterior uveitis market?
• What are the key regulatory events related to the anterior uveitis market?
• What is the structure of clinical trial landscape by status related to the anterior uveitis market?
• What is the structure of clinical trial landscape by phase related to the anterior uveitis market?
• What is the structure of clinical trial landscape by route of administration related to the anterior uveitis market?